Current status of third-line therapy for CML
Fabian Lang, MD, Goethe University, Frankfurt, Germany, comments on the tolerability and efficacy of asciminib in the treatment of patients with chronic myeloid leukemia (CML) in the third-line setting, highlighting the importance of improving the outcomes of this patient population and achieving a higher rate of treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео Current status of third-line therapy for CML онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 24 Октябрь 2022, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 97 раз и оно понравилось 0 людям.